Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07461142Not ApplicableNot Yet Recruiting

Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers

Role: collaborator

NCT04484181Not ApplicableActive Not Recruiting

What Embryoselection for What Chance of Success ? EmbryoSelect Study

Role: collaborator

NCT04481620Completed

Development and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT

Role: collaborator

All 3 trials loaded